Trial Profile

THE TREATMENT OF MULTIPLE MYELOMA UTILIZING VBMCP CHEMOTHERAPY ALTERNATING WITH HIGH-DOSE CYCLOPHOSPHAMIDE AND ALPHA 2B-INTERFERON VERSUS VBMCP: A PHASE III STUDY FOR PREVIOUSLY UNTREATED MULTIPLE MYELOMA.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Interferon alpha-2b (Primary) ; Carmustine; Melphalan; Prednisone; Vincristine
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use

31 May 2013 Biomarkers information updated
02 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
29 Sep 2005 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com